• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SiNtx Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    10/3/25 5:07:49 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care
    Get the next $SINT alert in real time by email
    false 0001269026 0001269026 2025-10-03 2025-10-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): October 3, 2025

     

    SINTX Technologies, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-33624   84-1375299

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    1885 West 2100 South

    Salt Lake City, UT 84119

    (Address of principal executive offices)(Zip Code)

     

    Registrant’s telephone number, including area code: (801) 839-3500

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:   Trading Symbol(s):   Name of each exchange on which registered:
    Common Stock, par value $0.01 per share   SINT   The NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On October 3, 2025, SINTX Technologies, Inc., a Delaware corporation (the “Company”) entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), to sell shares of its common stock, par value $0.01 per share (the “Shares”) from time to time, through an “at the market offering” program under which Wainwright will act as sales agent. The sales, if any, of the Shares made under the ATM Agreement will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), including, without limitation, sales made directly on or through the Nasdaq Capital Market or on any other existing trading market for the Company’s common stock.

     

    The Company will pay Wainwright a commission rate equal to 3.0% of the aggregate gross sales price from the sales of Shares pursuant to the ATM Agreement and has agreed to provide Wainwright with customary indemnification and contribution rights against certain liabilities, including liabilities under the Securities Act. The Company will also reimburse Wainwright for certain specified expenses in connection with entering into the ATM Agreement, including certain fees and out-of-pocket expenses of its legal counsel. The ATM Agreement contains customary representations and warranties and conditions to the sale of the Shares pursuant thereto.

     

    The Company is not obligated to sell any of the Shares under the ATM Agreement and may at any time suspend solicitation and offers thereunder. No assurance can be given that the Company will sell any Shares under the ATM Agreement, or if the Company does, as to the price or amount of Shares that the Company will sell, or the dates on which any such sales will take place. The offering of Shares pursuant to the ATM Agreement will terminate on the termination of the ATM Agreement by either the Company or Wainwright, as permitted therein.

     

    The Company will designate the maximum amount of common stock to be sold through Wainwright in any placement under the offering. Subject to the terms and conditions of the ATM Agreement, Wainwright has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell on the Company’s behalf all of the Shares requested to be sold by the Company.

     

    The Shares will be issued pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-274951) initially filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) on October 12, 2023, and declared effective by the SEC on November 27, 2023, and related prospectus supplements to be prepared and filed pursuant to Rule 424(b) from time to time in connection with the offer and sale of the Shares. A prospectus supplement (the “Prospectus Supplement”), dated October 3, 2025, covering the offer and sale of the Shares having an aggregate offering price of $6,413,876 was filed with the SEC on the date hereof.

     

    This Current Report does not constitute an offer to sell or the solicitation of an offer to buy any security nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

     

    The foregoing description of the ATM Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the ATM Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report and incorporated herein by reference. The ATM Agreement contains representations and warranties that the parties made to, and solely for the benefit of, the other in the context of all of the terms and conditions of the ATM Agreement and in the context of the specific relationship between the parties. The provisions of the ATM Agreement, including the representations and warranties contained therein, are not for the benefit of any party other than the parties to the ATM Agreement and are not intended as a document for investors and the public to obtain factual information about the Company’s current state of affairs. Rather, investors and the public should look to other disclosures contained in the Company’s filings with the SEC.

     

    Attached hereto as Exhibit 5.1, and incorporated by reference into the Prospectus Supplement, is the opinion of Dorsey & Whitney LLP relating to the legality of the issuance and sale of the Shares.

     

     Item 9.01 Financial Statements and Exhibits

     

    (d) Exhibits

     

    Exhibit No.   Description
    5.1   Opinion of Dorsey & Whitney LLP
    10.1   At The Market Offering Agreement, dated October 3, 2025, by and between the Company and H.C. Wainwright & Co., LLC
    23.1   Consent of Dorsey & Whitney LLP (included in Exhibit 5.1)
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          SINTX Technologies, Inc.
             
    Date: October 3, 2025   By: /s/ Eric K. Olson
            Eric K. Olson
            Chief Executive Officer

     

     

     

    Get the next $SINT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SINT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SINT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SINTX Technologies to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025

    SALT LAKE CITY, Utah, Sept. 09, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced that it has been invited to present at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. The Company's presentation is scheduled for Tuesday, September 9, 2025. "This event provides an important opportunity to share our objectives, highlight our progress, and engage directly with the institutional investor community," said Eric Olson, Chairman and

    9/9/25 7:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform Patent

    Significant Development in the Estimated $30 Billion Global Infection-Prevention Market SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance (PTOL-85) for its patent application titled, "Antipathogenic Fibrous Materials." The patent secures broad protection for SINTX's proprietary silicon nitride–based antipathogen platform. This allowance marks a significant intellectual property milestone for the Company, securing broad protection for the use of silicon nitride in multiple form factors designed to neu

    9/8/25 7:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Issues Business Update Following Strategic Realignment, Leadership Expansion, and SiNAPTIC Acquisition

    Company Reinforces Commercialization Focus and Strategic Direction SALT LAKE CITY, Utah, Aug. 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for medical device applications, today issued a business update in connection with the filing of the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed with the Securities and Exchange Commission and available at www.sec.gov. The business update highlights meaningful progress from the Company's recent SiNAPTIC acquisition, decisive strategic transformation, and a revitalized commercialization strategy

    8/15/25 7:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    SEC Filings

    View All

    SiNtx Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Sintx Technologies, Inc. (0001269026) (Filer)

    10/3/25 5:07:49 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by SiNtx Technologies Inc.

    424B5 - Sintx Technologies, Inc. (0001269026) (Filer)

    10/3/25 5:05:33 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by SiNtx Technologies Inc.

    S-8 - Sintx Technologies, Inc. (0001269026) (Filer)

    9/30/25 4:56:34 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moyes Jay M bought $10,756 worth of shares (3,000 units at $3.59) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    8/27/25 8:00:03 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Investment Officer Honigblum Gregg R. bought $185,000 worth of shares (50,000 units at $3.70), increasing direct ownership by 357% to 64,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    8/27/25 8:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    President and CEO Olson Eric K. bought $37,470 worth of shares (10,475 units at $3.58), increasing direct ownership by 72% to 24,975 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    8/25/25 5:14:09 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Trask Kevin

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    9/5/25 5:01:30 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    New insider Trask Kevin claimed ownership of 4,376 shares (SEC Form 3)

    3 - Sintx Technologies, Inc. (0001269026) (Issuer)

    9/5/25 5:00:28 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $10,756 worth of shares (3,000 units at $3.59) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    8/27/25 8:00:03 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

    Seasoned Healthcare Executive to Lead Strategic Growth Initiatives Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX's growth initiatives and enhancing investor relations. Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare secto

    11/19/24 6:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Financials

    Live finance-specific insights

    View All

    SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market

    Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities SALT LAKE CITY, Utah, June 24, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company focused on medical device innovation, today announced that it has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic manufacturing and innovation. This transaction is a significant milestone in SINTX's strategy to acquire a potential competitor and drive commercial revenue growth and expand its product portfolio in t

    6/24/25 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Acquires Technology Assessment and Transfer, Inc.

    The Acquisition Broadens Opportunities for SINTX in Aerospace, Defense, and Biomedical Markets SALT LAKE CITY, July 06, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced the acquisition of Technology Assessment and Transfer, Inc. (TA&T; https://www.techassess.com/), significantly increasing SINTX's capabilities in the aerospace, defense, and biomedical markets. "We are excited to acquire TA&T and take another step towards diversifying and strengthening SINTX," said Dr. Sonny Bal, President and CEO of SINTX. "TA&T will expand our use of advanced manufacturing techno

    7/6/22 9:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Issues 2022 10-K and Announces Investor Conference Call

    SALT LAKE CITY, March 25, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced today the filing of its Annual Report on Form 10-K for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission. In 2021, SINTX made significant investments into the expansion of its three priority business segments - biomedical, industrial/armor, and antipathogenic - through the purchase of new technology, equipment, and personnel. The Company is narrowly focused on opportunities closest to revenue such as armor materials and plates, the development of new biomedi

    3/25/22 5:41:39 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by SiNtx Technologies Inc.

    SC 13G - Sintx Technologies, Inc. (0001269026) (Subject)

    4/1/24 4:17:43 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by SiNtx Technologies Inc. (Amendment)

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    2/13/24 8:12:54 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care